<?xml version='1.0' encoding='utf-8'?>
<document id="21976621"><sentence text="Prediction of CYP2D6 drug interactions from in vitro data: evidence for substrate-dependent inhibition." /><sentence text="Predicting the magnitude of potential drug-drug interactions is important for underwriting patient safety in the clinical setting" /><sentence text=" Substrate-dependent inhibition of cytochrome P450 enzymes may confound extrapolation of in vitro results to the in vivo situation" /><sentence text=" However, the potential for substrate-dependent inhibition with CYP2D6 has not been well characterized" /><sentence text=" The inhibition profiles of 20 known inhibitors of CYP2D6 were characterized in vitro against four clinically relevant CYP2D6 substrates (desipramine, dextromethorphan, metoprolol, and thioridazine) and bufuralol"><entity charOffset="138-149" id="DDI-PubMed.21976621.s5.e0" text="desipramine" /><entity charOffset="151-167" id="DDI-PubMed.21976621.s5.e1" text="dextromethorphan" /><entity charOffset="169-179" id="DDI-PubMed.21976621.s5.e2" text="metoprolol" /><entity charOffset="185-197" id="DDI-PubMed.21976621.s5.e3" text="thioridazine" /><entity charOffset="203-212" id="DDI-PubMed.21976621.s5.e4" text="bufuralol" /><pair ddi="false" e1="DDI-PubMed.21976621.s5.e0" e2="DDI-PubMed.21976621.s5.e0" /><pair ddi="false" e1="DDI-PubMed.21976621.s5.e0" e2="DDI-PubMed.21976621.s5.e1" /><pair ddi="false" e1="DDI-PubMed.21976621.s5.e0" e2="DDI-PubMed.21976621.s5.e2" /><pair ddi="false" e1="DDI-PubMed.21976621.s5.e0" e2="DDI-PubMed.21976621.s5.e3" /><pair ddi="false" e1="DDI-PubMed.21976621.s5.e0" e2="DDI-PubMed.21976621.s5.e4" /><pair ddi="false" e1="DDI-PubMed.21976621.s5.e1" e2="DDI-PubMed.21976621.s5.e1" /><pair ddi="false" e1="DDI-PubMed.21976621.s5.e1" e2="DDI-PubMed.21976621.s5.e2" /><pair ddi="false" e1="DDI-PubMed.21976621.s5.e1" e2="DDI-PubMed.21976621.s5.e3" /><pair ddi="false" e1="DDI-PubMed.21976621.s5.e1" e2="DDI-PubMed.21976621.s5.e4" /><pair ddi="false" e1="DDI-PubMed.21976621.s5.e2" e2="DDI-PubMed.21976621.s5.e2" /><pair ddi="false" e1="DDI-PubMed.21976621.s5.e2" e2="DDI-PubMed.21976621.s5.e3" /><pair ddi="false" e1="DDI-PubMed.21976621.s5.e2" e2="DDI-PubMed.21976621.s5.e4" /><pair ddi="false" e1="DDI-PubMed.21976621.s5.e3" e2="DDI-PubMed.21976621.s5.e3" /><pair ddi="false" e1="DDI-PubMed.21976621.s5.e3" e2="DDI-PubMed.21976621.s5.e4" /></sentence><sentence text=" Dextromethorphan exhibited the highest sensitivity to in vitro inhibition, whereas metoprolol was the least sensitive"><entity charOffset="1-17" id="DDI-PubMed.21976621.s6.e0" text="Dextromethorphan" /><entity charOffset="84-94" id="DDI-PubMed.21976621.s6.e1" text="metoprolol" /><pair ddi="false" e1="DDI-PubMed.21976621.s6.e0" e2="DDI-PubMed.21976621.s6.e0" /><pair ddi="false" e1="DDI-PubMed.21976621.s6.e0" e2="DDI-PubMed.21976621.s6.e1" /></sentence><sentence text=" In addition, when metoprolol was the substrate, inhibitors with structurally constrained amino moieties (clozapine, debrisoquine, harmine, quinidine, and yohimbine) exhibited at least a 5-fold decrease in inhibition potency when results were compared with those for dextromethorphan"><entity charOffset="19-29" id="DDI-PubMed.21976621.s7.e0" text="metoprolol" /><entity charOffset="90-95" id="DDI-PubMed.21976621.s7.e1" text="amino" /><entity charOffset="106-115" id="DDI-PubMed.21976621.s7.e2" text="clozapine" /><entity charOffset="117-129" id="DDI-PubMed.21976621.s7.e3" text="debrisoquine" /><entity charOffset="131-138" id="DDI-PubMed.21976621.s7.e4" text="harmine" /><entity charOffset="140-149" id="DDI-PubMed.21976621.s7.e5" text="quinidine" /><entity charOffset="155-164" id="DDI-PubMed.21976621.s7.e6" text="yohimbine" /><entity charOffset="267-283" id="DDI-PubMed.21976621.s7.e7" text="dextromethorphan" /><pair ddi="false" e1="DDI-PubMed.21976621.s7.e0" e2="DDI-PubMed.21976621.s7.e0" /><pair ddi="false" e1="DDI-PubMed.21976621.s7.e0" e2="DDI-PubMed.21976621.s7.e1" /><pair ddi="false" e1="DDI-PubMed.21976621.s7.e0" e2="DDI-PubMed.21976621.s7.e2" /><pair ddi="false" e1="DDI-PubMed.21976621.s7.e0" e2="DDI-PubMed.21976621.s7.e3" /><pair ddi="false" e1="DDI-PubMed.21976621.s7.e0" e2="DDI-PubMed.21976621.s7.e4" /><pair ddi="false" e1="DDI-PubMed.21976621.s7.e0" e2="DDI-PubMed.21976621.s7.e5" /><pair ddi="false" e1="DDI-PubMed.21976621.s7.e0" e2="DDI-PubMed.21976621.s7.e6" /><pair ddi="false" e1="DDI-PubMed.21976621.s7.e0" e2="DDI-PubMed.21976621.s7.e7" /><pair ddi="false" e1="DDI-PubMed.21976621.s7.e1" e2="DDI-PubMed.21976621.s7.e1" /><pair ddi="false" e1="DDI-PubMed.21976621.s7.e1" e2="DDI-PubMed.21976621.s7.e2" /><pair ddi="false" e1="DDI-PubMed.21976621.s7.e1" e2="DDI-PubMed.21976621.s7.e3" /><pair ddi="false" e1="DDI-PubMed.21976621.s7.e1" e2="DDI-PubMed.21976621.s7.e4" /><pair ddi="false" e1="DDI-PubMed.21976621.s7.e1" e2="DDI-PubMed.21976621.s7.e5" /><pair ddi="false" e1="DDI-PubMed.21976621.s7.e1" e2="DDI-PubMed.21976621.s7.e6" /><pair ddi="false" e1="DDI-PubMed.21976621.s7.e1" e2="DDI-PubMed.21976621.s7.e7" /><pair ddi="false" e1="DDI-PubMed.21976621.s7.e2" e2="DDI-PubMed.21976621.s7.e2" /><pair ddi="false" e1="DDI-PubMed.21976621.s7.e2" e2="DDI-PubMed.21976621.s7.e3" /><pair ddi="false" e1="DDI-PubMed.21976621.s7.e2" e2="DDI-PubMed.21976621.s7.e4" /><pair ddi="false" e1="DDI-PubMed.21976621.s7.e2" e2="DDI-PubMed.21976621.s7.e5" /><pair ddi="false" e1="DDI-PubMed.21976621.s7.e2" e2="DDI-PubMed.21976621.s7.e6" /><pair ddi="false" e1="DDI-PubMed.21976621.s7.e2" e2="DDI-PubMed.21976621.s7.e7" /><pair ddi="false" e1="DDI-PubMed.21976621.s7.e3" e2="DDI-PubMed.21976621.s7.e3" /><pair ddi="false" e1="DDI-PubMed.21976621.s7.e3" e2="DDI-PubMed.21976621.s7.e4" /><pair ddi="false" e1="DDI-PubMed.21976621.s7.e3" e2="DDI-PubMed.21976621.s7.e5" /><pair ddi="false" e1="DDI-PubMed.21976621.s7.e3" e2="DDI-PubMed.21976621.s7.e6" /><pair ddi="false" e1="DDI-PubMed.21976621.s7.e3" e2="DDI-PubMed.21976621.s7.e7" /><pair ddi="false" e1="DDI-PubMed.21976621.s7.e4" e2="DDI-PubMed.21976621.s7.e4" /><pair ddi="false" e1="DDI-PubMed.21976621.s7.e4" e2="DDI-PubMed.21976621.s7.e5" /><pair ddi="false" e1="DDI-PubMed.21976621.s7.e4" e2="DDI-PubMed.21976621.s7.e6" /><pair ddi="false" e1="DDI-PubMed.21976621.s7.e4" e2="DDI-PubMed.21976621.s7.e7" /><pair ddi="false" e1="DDI-PubMed.21976621.s7.e5" e2="DDI-PubMed.21976621.s7.e5" /><pair ddi="false" e1="DDI-PubMed.21976621.s7.e5" e2="DDI-PubMed.21976621.s7.e6" /><pair ddi="false" e1="DDI-PubMed.21976621.s7.e5" e2="DDI-PubMed.21976621.s7.e7" /><pair ddi="false" e1="DDI-PubMed.21976621.s7.e6" e2="DDI-PubMed.21976621.s7.e6" /><pair ddi="false" e1="DDI-PubMed.21976621.s7.e6" e2="DDI-PubMed.21976621.s7.e7" /></sentence><sentence text=" Atypical inhibition kinetics were observed for these and other inhibitor-substrate pairings" /><sentence text=" In silico docking studies suggested that interactions with Glu216 and an adjacent hydrophobic binding pocket may influence substrate sensitivity and inhibition potency for CYP2D6" /><sentence text=" The in vivo sensitivities of the clinically relevant CYP2D6 substrates desipramine, dextromethorphan, and metoprolol were determined on the basis of literature drug-drug interaction (DDI) outcomes"><entity charOffset="72-83" id="DDI-PubMed.21976621.s10.e0" text="desipramine" /><entity charOffset="85-101" id="DDI-PubMed.21976621.s10.e1" text="dextromethorphan" /><entity charOffset="107-117" id="DDI-PubMed.21976621.s10.e2" text="metoprolol" /><pair ddi="false" e1="DDI-PubMed.21976621.s10.e0" e2="DDI-PubMed.21976621.s10.e0" /><pair ddi="false" e1="DDI-PubMed.21976621.s10.e0" e2="DDI-PubMed.21976621.s10.e1" /><pair ddi="false" e1="DDI-PubMed.21976621.s10.e0" e2="DDI-PubMed.21976621.s10.e2" /><pair ddi="false" e1="DDI-PubMed.21976621.s10.e1" e2="DDI-PubMed.21976621.s10.e1" /><pair ddi="false" e1="DDI-PubMed.21976621.s10.e1" e2="DDI-PubMed.21976621.s10.e2" /></sentence><sentence text=" Similar to the in vitro results, dextromethorphan exhibited the highest sensitivity to CYP2D6 inhibition in vivo"><entity charOffset="34-50" id="DDI-PubMed.21976621.s11.e0" text="dextromethorphan" /></sentence><sentence text=" Finally, the magnitude of in vivo CYP2D6 DDIs caused by quinidine was predicted using desipramine, dextromethorphan, and metoprolol"><entity charOffset="57-66" id="DDI-PubMed.21976621.s12.e0" text="quinidine" /><entity charOffset="87-98" id="DDI-PubMed.21976621.s12.e1" text="desipramine" /><entity charOffset="100-116" id="DDI-PubMed.21976621.s12.e2" text="dextromethorphan" /><entity charOffset="122-132" id="DDI-PubMed.21976621.s12.e3" text="metoprolol" /><pair ddi="false" e1="DDI-PubMed.21976621.s12.e0" e2="DDI-PubMed.21976621.s12.e0" /><pair ddi="false" e1="DDI-PubMed.21976621.s12.e0" e2="DDI-PubMed.21976621.s12.e1" /><pair ddi="false" e1="DDI-PubMed.21976621.s12.e0" e2="DDI-PubMed.21976621.s12.e2" /><pair ddi="false" e1="DDI-PubMed.21976621.s12.e0" e2="DDI-PubMed.21976621.s12.e3" /><pair ddi="false" e1="DDI-PubMed.21976621.s12.e1" e2="DDI-PubMed.21976621.s12.e1" /><pair ddi="false" e1="DDI-PubMed.21976621.s12.e1" e2="DDI-PubMed.21976621.s12.e2" /><pair ddi="false" e1="DDI-PubMed.21976621.s12.e1" e2="DDI-PubMed.21976621.s12.e3" /><pair ddi="false" e1="DDI-PubMed.21976621.s12.e2" e2="DDI-PubMed.21976621.s12.e2" /><pair ddi="false" e1="DDI-PubMed.21976621.s12.e2" e2="DDI-PubMed.21976621.s12.e3" /></sentence><sentence text=" Comparisons of the predictions with literature results indicated that the marked decrease in inhibition potency observed for the metoprolol-quinidine interaction in vitro translated to the in vivo situation" /><sentence text="" /></document>